Locations
Palo Alto, CA, USA · Los Altos, CA, USA
industry
Biotechnology · DeepTech · Health
Size
51-200 employees
Stage
Series C+
founded in
2020
Evommune is focused on discovering and developing novel therapies for chronic inflammatory diseases, targeting the root causes of inflammation with a robust pipeline that includes the MRGPRX2 Antagonist, IL-18 Fusion Protein, and PKCθ Inhibitor. The company aims to address the high unmet needs in underserved patient populations, leveraging extensive R&D expertise in immunology to deliver therapeutics that go beyond symptomatic relief. With a commitment to advancing clinical-stage pipelines, Evommune is positioned to make significant impacts in the treatment of chronic inflammatory diseases, which are increasingly recognized as a global health crisis.
Something looks off?On-site & Remote